1996PubMedRequires access

[The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma].

Xiangzhan Kong, Fu Deng, J Wang

Open publisher page 1 citations

Abstract

In order to understand the characteristics of proliferative and malignant prostate lesions and to improve the differential diagnosis, immunohistochemical methods using high molecular weight cytokeratin monoclonal antibody 34BE12 to stain the basal cells and to differentiate prostate cancer from hyperplasia in 82 prostate biopsies and specimens, which included 21 adenocarcinoma, 30 intraepithelial neoplasia, 5 atypical adenomatous hyperplasia, 8 basal cell hyperplasia, 11 atrophy of prostate, 4 postatrophic hyperplasia and 3 cribriform hyperplasia. It was demonstrated that the basal cell layer was lost in all prostate adenocarcinomas, but existed in most of the proliferative lesions except for atypical adenomatous hyperplasia and grade 3 intra-epithelial neoplasia in which the basal layer was disrupted in some cases. The study showed that the 34BE12 antibody was useful in the differential diagnosis of prostate adenocarcinoma.

About this research paper

What this paper is about

In order to understand the characteristics of proliferative and malignant prostate lesions and to improve the differential diagnosis, immunohistochemical methods using high molecular weight cytokeratin monoclonal antibody 34BE12 to stain the basal cells and to differentiate prostate cancer from hyperplasia in 82 prostate biopsies and specimens, which included 21 adenocarcinoma, 30 intraepithelial neoplasia, 5 atypical adenomatous hyperplasia, 8 basal cell hyperplasia, 11 atrophy of prostate, 4 postatrophic hyperplasia and 3 cribriform hyperplasia. It was demonstrated that the basal cell layer was lost in all prostate adenocarcinomas, but existed in most of the proliferative lesions except for atypical adenomatous hyperplasia and grade 3 intra-epithelial neoplasia in which the basal layer was disrupted in some cases. The study showed that the 34BE12 antibody was useful in the differential diagnosis of prostate adenocarcinoma.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In order to understand the characteristics of proliferative and malignant prostate lesions and to improve the differential diagnosis, immunohistochemical methods using high molecular weight cytokeratin monoclonal antibody 34BE12 to stain the basal cells and to differentiate prostate cancer from hyperplasia in 82 prostate biopsies and specimens, which included 21 adenocarcinoma, 30 intraepithelial neoplasia, 5 atypical adenomatous hyperplasia, 8 basal cell hyperplasia, 11 atrophy of prostate, 4 postatrophic hyperplasia and 3 cribriform hyperplasia. It was demonstrated that the basal cell layer was lost in all prostate adenocarcinomas, but existed in most of the proliferative lesions except for atypical adenomatous hyperplasia and grade 3 intra-epithelial neoplasia in which the basal layer was disrupted in some cases. The study showed that the 34BE12 antibody was useful in the differential diagnosis of prostate adenocarcinoma.

Key concepts: Atypical adenomatous hyperplasia, Pathology, Cytokeratin, Hyperplasia, Differential diagnosis, Adenocarcinoma, Intraepithelial neoplasia, Prostate cancer

Related papers

Back to paper searchBrowse research topicsOriginal source
[The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma]. — Research Paper | ScholarLens